GEODE CAPITAL MANAGEMENT, LLC - DECIPHERA PHARMACEUTICALS IN ownership

DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 157 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.2%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of DECIPHERA PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$14,459,495
-7.4%
1,136,607
+2.5%
0.00%0.0%
Q2 2023$15,620,426
-5.2%
1,109,405
+4.1%
0.00%0.0%
Q1 2023$16,471,312
+110171.9%
1,066,104
+17.0%
0.00%0.0%
Q4 2022$14,937
-99.9%
911,394
+3.8%
0.00%0.0%
Q3 2022$16,237,000
+49.6%
877,693
+6.3%
0.00%0.0%
Q2 2022$10,856,000
+82.6%
825,606
+28.7%
0.00%
+100.0%
Q1 2022$5,944,000
-22.3%
641,264
-18.1%
0.00%0.0%
Q4 2021$7,654,000
-69.5%
783,455
+6.1%
0.00%
-66.7%
Q3 2021$25,102,000
-7.4%
738,758
-0.2%
0.00%
-25.0%
Q2 2021$27,103,000
-14.1%
740,330
+5.2%
0.00%
-20.0%
Q1 2021$31,570,000
-15.3%
704,063
+7.8%
0.01%
-16.7%
Q4 2020$37,257,000
+17.7%
652,839
+5.8%
0.01%0.0%
Q3 2020$31,666,000
+17.6%
617,287
+36.9%
0.01%0.0%
Q2 2020$26,919,000
+94.7%
450,768
+34.2%
0.01%
+50.0%
Q1 2020$13,823,000
-62.6%
335,778
-43.4%
0.00%0.0%
Q4 2019$36,948,000
+283.4%
593,640
+109.1%
0.00%
+100.0%
Q3 2019$9,637,000
+97.2%
283,962
+31.0%
0.00%
+100.0%
Q2 2019$4,888,000
+15.9%
216,807
+19.3%
0.00%0.0%
Q1 2019$4,218,000
-39.8%
181,746
-45.6%
0.00%0.0%
Q4 2018$7,006,000
+29.5%
333,808
+138.9%
0.00%
-50.0%
Q3 2018$5,411,000
+4.3%
139,747
+6.0%
0.00%0.0%
Q2 2018$5,186,000
+126.4%
131,794
+15.3%
0.00%
+100.0%
Q1 2018$2,291,000
-16.2%
114,332
-5.2%
0.00%0.0%
Q4 2017$2,735,000120,6510.00%
Other shareholders
DECIPHERA PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
New Leaf Venture Partners, L.L.C. 1,209,571$69,030,00015.95%
SV Health Investors, LLC 449,951$25,679,00012.37%
Sunesis Advisors, LLC 96,299$5,496,0004.45%
Redmile Group, LLC 4,437,968$253,275,0003.07%
Consonance Capital Management LP 484,671$27,660,0002.58%
SECTORAL ASSET MANAGEMENT INC 488,842$27,898,0001.97%
Opaleye Management Inc. 222,000$12,670,0001.66%
Eversept Partners, LP 246,240$14,052,9171.65%
SILVERARC CAPITAL MANAGEMENT, LLC 38,620$2,204,0001.28%
Avoro Capital Advisors LLC 1,300,000$74,191,0001.28%
View complete list of DECIPHERA PHARMACEUTICALS IN shareholders